Could a vaccine stop cancer before it starts in lynch syndrome?

NCT ID NCT07412197

Not yet recruiting Prevention Sponsor: Radboud University Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a personalized vaccine made from a person's own immune cells (dendritic cells) loaded with cancer-specific markers. The goal is to train the immune system to recognize and destroy precancerous cells in people with Lynch syndrome, who have a high risk of several cancers. The study will enroll 13 participants without active cancer to see if the vaccine is safe, feasible to produce, and triggers an immune response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dendritic cell vaccine loaded with neopeptides
What this could lead to: If successful, this could lead to a vaccine that prevents cancer in people with Lynch syndrome, reducing their lifetime cancer risk.
What could go wrong: This is a very early phase 1/2 trial with only 13 participants, so it is primarily testing safety and feasibility. The vaccine may not trigger a strong enough immune response or prevent tumors long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYNCH SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Colorectal Neoplasms, Hereditary Nonpolyposis Lynch syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYNCH SYNDROME

Contacts and locations

Show contact details

Locations

Radboudumc

Nijmegen, Netherlands

Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.